Theranostic drug unites imaging and therapy for prostate cancer

A novel molecular imaging technology not only detects prostate cancer that has spread throughout the body, but also provides a potent and minimally invasive method of radiotherapy, reveal researchers.

The emerging technology portrays a theranostic drug called PSMA-617, a prostate-specific membrane antigen inhibitor that targets the enzyme on the surface of prostate cancer cells, even if they have spread, or metastasized, to other organs. Read more.